Bio-Techne Stock

Bio-Techne EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Bio-Techne (TECH) as of Jul 24, 2026 is 87.65. In the previous year, EV/EBIT (Enterprise Value to EBIT) was 45.36 — a change of 93.22% (higher).

EV/EBIT

87.65

YoY

93.22%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Bio-Techne is 2026 87.65 . EV/EBIT (Enterprise Value to EBIT) of Bio-Techne was 2025 45.36 . It decreases by 93.22% higher compared to the previous year.

The Bio-Techne EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2019
69.13 base
Jan 1, 2020
72.63 base
Jan 1, 2021
89.84 base
Jan 1, 2022
43.65 base
Jan 1, 2023
40.26 base
Jan 1, 2024
55.98 base
Jan 1, 2025
86.31 base
Jan 1, 2026 (e)
28.68 base
YEARPRICE-TO-EBIT
2026 est 28.68
2025 86.31
2024 55.98
2023 40.26
2022 43.65
2021 89.84
2020 72.63
2019 69.13
2018 41.18
2017 40.34
2016 25.59
2015 22.83
2014 21.52
2013 22.11
2012 15.17
2011 15.50
2010 15.61
2009 16.98
2008 16.99
2007 21.01
2006 20.19
Access this data via the Eulerpool API

Bio-Techne Valuation

Details

Historical Valuation Multiples

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Bio-Techne's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Bio-Techne's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Bio-Techne's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Bio-Techne grows earnings faster than its peers.

Bio-Techne Stock analysis

What does Bio-Techne do? Bio-Techne Corp is a global company specializing in the research and development of innovative products and solutions in the field of biosciences. The company was founded in 1976 in Minneapolis and was formerly known as Techne Corporation. Since then, it has grown into an internationally renowned company through its numerous acquisitions and mergers. The company is headquartered in Minneapolis, Minnesota, USA. The business philosophy of Bio-Techne Corp is to help bioscientific researchers and clinicians around the world perform their work more effectively, efficiently, and quickly. The company works closely with its customers to provide them with suitable products and services, thereby developing innovative solutions to the challenges in bioscience. Bio-Techne Corp has various business segments, including protein platforms, diagnostics, genetic analysis, clinical controls, cell culture products, and research reagents. Each business segment offers a variety of products and services to support researchers and clinicians in their work. A key business segment of Bio-Techne Corp is the protein platform, which offers a comprehensive range of proteins, antibodies, and corresponding detection reagents. The company is known for its high-quality proteins and antibodies, which contribute to improving the research of diseases such as cancer, diabetes, and neurological and immunological disorders. Another important business segment of Bio-Techne Corp is diagnostics. Here, the company offers a wide range of clinical diagnostic products, such as tests for analyzing urea, creatinine, and bone density. The company's products help clinicians make precise diagnoses and treat patients more effectively. The genetic analysis segment offers DNA sequencing, gene expression, and genome-wide analysis products and services. These tools enable researchers to better understand the functioning of the human body by exploring the underlying genetic changes. The clinical controls segment offers product and service offerings that improve the reliability and accuracy of diagnostic systems. The company works closely with medical facilities to provide diagnostic solutions that deliver fast and accurate results. The cell culture products segment offers a complete range of solutions for cell cultivation and growth. The offering ranges from basic nutrient media and additives to culture vessels and accessories. The company's products enable researchers to culture cells in a controlled environment and under precise conditions. The last segment of Bio-Techne Corp includes research reagents. Here, the company offers a wide range of reagents used for protein, antibody, and cell function analysis and research. The products meet the needs of researchers in modern bioscience. In summary, Bio-Techne Corp is a company specialized in developing innovative solutions in bioscience, advancing science and medicine. With its products and services offered in various sectors, the company successfully helps researchers and clinicians perform their work faster, more effectively, and cost-efficiently. Bio-Techne is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bio-Techne stock

EV/EBIT (Enterprise Value to EBIT) of Bio-Techne is 87.65 in 2026.

Access this data via the Eulerpool API

Valuation — Bio-Techne

All Key Metrics — Bio-Techne